http://www.curefa.org/press08-09-11.html 

September 12, 2008- BGC Partners, Inc. selected the Friedreich's Ataxia Research Alliance (FARA) to be one of their 2008 Charity Day recipients. BGC's Charity Day was originally conceived as a way to raise money for the Cantor Relief Fund, by donating a full day's global brokerage commissions to the Fund. Today the event has evolved and funds raised now also go to dozens of other worthy causes around the world.

In 2007 BGC raised over $6 million globally. In New York the event is held in their Wall Street offices, with invited celebrity guests acting as brokers for the day. With the guidance of BGC's licensed brokers, they carry out actual trades of bonds, foreign exchange and other financial instruments with BGC clients- Wall Street's biggest banks. On September 11, 2008, Sean Landeta- retired NY Giants punter, Tiki Barber- retired NY Giants running back and current Today Show correspondent, and Rich Monteleone- NY Yankees Special Pitching Instructor represented FARA on the trading floor for Charity Day.

BGC Partners, Inc. (Nasdaq: BGCP) is one of the world’s leading inter-dealer brokers. The company was formed as Cantor Fitzgerald rebuilt after the World Trade Center attacks, and was separated from Cantor in 2004. Daniel M. LaVecchia, Executive Managing Director for the Americas at BGC commented, "We're delighted to be supporting FARA at BGC's fourth annual Charity Day. In just a decade, FARA has made enormous strides towards better understanding and finding a cure for Friedreich's Ataxia. We're very pleased to be able to help them advance this cause."

Friedreich's Ataxia (FA) is a debilitating, life-shortening, degenerative neuro-muscular disorder. Onset of symptoms can vary from childhood to adulthood and includes loss of coordination and balance as well as muscle loss and fatigue. Additional complications of FA can include diabetes, scoliosis (severe curvature of the spine), and cardiomyopathy (a serious heart condition).

Jennifer Farmer, Executive Director for FARA, stated, “On a day marked by tragedy, BGC pays tribute to those lost by engaging in acts of service and giving. Charity Day honors the past by making a difference in communities today. FARA is grateful for BGC's support of our efforts to improve FA patients quality of life through research into treatments and a cure for FA.”

About FARA 
The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for Friedreich's ataxia. 
http://www.CureFA.org

Contact:

Jennifer Farmer

Executive Director, FARA

(484) 875 3015

This email address is being protected from spambots. You need JavaScript enabled to view it. 

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top